Noncardiac Comorbidities in Chronic Heart Failure: More Is Worse, What Else Do We Know?
- PMID: 37452804
- DOI: 10.1016/j.jchf.2023.06.011
Noncardiac Comorbidities in Chronic Heart Failure: More Is Worse, What Else Do We Know?
Keywords: chronic heart failure; exercise capacity; noncardiac comorbidities.
Conflict of interest statement
Funding Support and Author Disclosures Dr Mentz has received research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Eli Lilly, Medtronic, Medable, Merck, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Relypsa, Respicardia, Roche, Sanofi, Vifor, Windtree Therapeutics, and Zoll. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Comment on
-
Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure.JACC Heart Fail. 2023 Oct;11(10):1365-1376. doi: 10.1016/j.jchf.2023.05.018. Epub 2023 Jun 28. JACC Heart Fail. 2023. PMID: 37389503
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
